There are 2789 resources available
1259P - Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Presenter: Xiuning Le
Session: ePoster Display
1295P - Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
Presenter: Mathilde Bureau
Session: ePoster Display
1296P - Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Presenter: Alberto Bongiovanni
Session: ePoster Display
1382P - Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer
Presenter: Jeeyun Lee
Session: ePoster Display
1383P - Phase I study of the irreversible FGFR inhibitor futibatinib in Japanese patients with advanced solid tumors: Updated dose expansion results and activity in gastric cancer
Presenter: Yasutoshi Kuboki
Session: ePoster Display
1298P - PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Presenter: Sally Lau
Session: ePoster Display
1299P - Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Presenter: Konstantinos Rounis
Session: ePoster Display
1300P - A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Presenter: lin wu
Session: ePoster Display
1301P - Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
Presenter: Ari VanderWalde
Session: ePoster Display